oxaliplatin + tegafur

Oxaliplatin + tegafur is a combination chemotherapy regimen primarily used in the treatment of advanced gastric and colorectal cancers. Oxaliplatin is a third-generation platinum-based antineoplastic agent that forms DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death. Tegafur is an oral prodrug of 5-fluorouracil (5-FU), which acts as an antimetabolite by interfering with DNA synthesis in rapidly dividing cancer cells. This combination may be administered as part of the SOX regimen (S-1 [tegafur/gimeracil/oteracil] plus oxaliplatin) or as a simpler two-drug protocol, depending on clinical context. The combination has demonstrated efficacy in neoadjuvant and first-line settings for advanced gastric cancer and metastatic colorectal cancer[1][2][3][8]. Tegafur’s conversion to 5-FU allows for continuous exposure to cytotoxic effects with improved oral bioavailability compared to intravenous 5-FU.

Other names

SOX regimen